ArticleCells2026
Cilastatin Protects Against Chemotherapy-Induced Neuropathy via the FKBP51/DPEP1 Axis: Confocal Insights into Protein Dynamics.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dorsal root ganglion (DRG) neuroinflammation is a hallmark feature of oxaliplatin-induced peripheral neuropathy (OIPN), a dose-limiting side effect with poorly understood molecular mechanisms. In this study, we investigated the protective potential of cilastatin (CIL), a dipeptidase 1 (DPEP1) inhibitor, while elucidating the regulatory roles of FK506-binding protein 51 (FKBP51) and DPEP1 in OIPN pathogenesis. Behavioral allodynia was evaluated using the acetone test in an oxaliplatin (OxPt) rat model. Lumbar DRGs were imaged via advanced confocal microscopy (Zeiss LSM980 Airyscan 2, Zeiss, Oberkochen, Germany) and analyzed using Fiji 1.54t software to determine fluorescence intensity, subcellular distribution, and co-localization metrics (Pearson's and Manders' coefficients). OxPt administration induced marked downregulation and cytoplasmic-to-nuclear translocation of FKBP51 within DRG neuronal and glial compartments. Notably, FKBP51 frequently co-localized with DPEP1 and the pro-inflammatory cytokines TNF-α and IL-6. DPEP1 was strongly expressed in DRG neurons, where it exhibited enhanced perinuclear localization. Concomitant CIL treatment significantly reversed these alterations by attenuating the OxPt-induced cell-type- and compartment-specific changes in FKBP51 and DPEP1 distribution, suppressing TNF-α and IL-6 expression, and preventing GFAP overexpression. These findings identify a novel interplay between FKBP51 and DPEP1 within the DRG during OIPN-elicited neuroinflammation, potentially linking stress protein signaling to pro-inflammatory cytokine activation. Consequently, CIL represents a promising therapeutic candidate to prevent chemotherapy-induced neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.